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ABSTRACT
Acinetobacter baumannii is now one of the most frequently encountered nosocomial pathogens in
intensive therapy units, and is renowned for being difﬁcult to treat because of resistance to most
antibiotics. Carbapenems are the remaining drugs of choice in many centres, but carbapenem resistance
is now emerging in strains worldwide. Two subgroups of carbapenem-hydrolysing b-lactamases, which
differ in their amino-acid homology, have been found in some resistant strains. This report describes the
emergence and characterisation of a novel carbapenemase (OXA-51) in genetically distinct carbapenem-
resistant A. baumannii strains from Argentina. Enzyme kinetics and inhibitor studies were performed
spectrophotometrically with puriﬁed b-lactamase. Ampliﬁcation of the gene was achieved with a two-
step PCR method employing arbitrary partially degenerate and gene-speciﬁc primers. Transfer of
imipenem resistance was attempted with the use of broth and membrane ﬁlter methods. Attempts to
produce plasmid-cured variants were made in ethidium bromide curing experiments. OXA-51 was
identiﬁed in two clones of A. baumannii, and was found to have < 63% amino-acid identity with
subgroups 1 and 2. Enzyme kinetic studies conﬁrmed that OXA-51 was a molecular class D enzyme with
carbapenemase activity, and that it displayed the highest afﬁnity for imipenem (Km value 11 lM).
Sequence analysis of the gene identiﬁed distinct differences within conserved class D motifs when
compared with subgroups 1 and 2. Attempts to transfer imipenem resistance and to determine a
plasmid location for the gene failed. OXA-51 is the ﬁrst of a new subgroup of carbapenemases to emerge
in multiresistant clinical isolates of A. baumannii.
Keywords Acinetobacter baumannii, b-lactamase, carbapenemase, imipenem, OXA-51, resistance
Original Submission: 23 July 2004; Revised Submission: 26 August 2004; Accepted: 2 September 2004
Clin Microbiol Infect 2005; 11: 15–23
INTRODUCTION
The incidence and spread of resistant bacteria
within hospitals are now of global concern. While
much attention has been focused on methicillin-
resistant Staphylococcus aureus, the incidence of the
Gram-negative organism Acinetobacter baumannii
as a causal agent of infection has increased steadily
[1]. Acinetobacters are renowned for their ability to
survive in the environment in dry conditions
for prolonged periods, and environmental
contamination represents an important reservoir
for their dissemination [2]. A. baumannii is the
species isolated most frequently, and is now
recognised as an important cause of infection,
particularly in compromised patients with such
risk factors as mechanical ventilation, surgery and
prolonged stays in the intensive therapy unit (ITU)
[1,3]. In many hospitals,A. baumannii is now one of
the most commonly encountered Gram-negative
pathogens in the ITU [4,5].
A. baumannii has the ability to rapidly acquire
resistance to most antibiotics [6], and the world-
wide emergence of multiresistant strains that are
also resistant to the carbapenems, a class of
antibiotic that has been the mainstay of therapy
for infections caused by resistant strains, has been
a worrying trend. Consequently, the use of these
antibiotics has become seriously compromised
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[7]. Major outbreaks of carbapenem-resistant
strains have been reported in many centres
worldwide [8–13], and pan-drug resistance is
now emerging [14,15]. b-Lactamase-mediated
carbapenem resistance is being reported with
increasing frequency in clinical strains, and sev-
eral Ambler class B metallo-b-lactamases of the
IMP and VIM families have been identiﬁed,
predominantly in isolates from parts of Asia,
southern Europe [16–19] and the UK [20,21].
An additional unexpected development has
been the discovery worldwide of molecular class
D b-lactamases in clinical isolates that have
acquired the ability to hydrolyse carbapenems.
These OXA-type enzymes are normally found in
bacteria such as Pseudomonas aeruginosa, and are
not usually associated with carbapenem resist-
ance [22]. So far, two subgroups of OXA-type
carbapenemases have been identiﬁed in A. bau-
mannii. The ﬁrst such enzyme, OXA-23, was
identiﬁed in an isolate from a patient in Edin-
burgh, and along with OXA-27, isolated in Sin-
gapore, comprises subgroup 1, both sharing 99%
amino-acid identity [23–25]. The sequence of
another carbapenemase, OXA-49 (China), has
been reported (GenBank ⁄EMBL accession num-
ber AY288523), but the speciﬁc details have yet to
be published. However, based on amino-acid
identity, it also belongs to subgroup 1. Subgroup
2 comprises OXA-24, -25, -26 and -40, which were
identiﬁed in isolates from Spain, Belgium, France
and Portugal, and which differ by one or two
amino-acids [25–27]. Subgroups 1 and 2 share
60% identity, and a characteristic of both is the
presence of a phenylalanine (Phe) residue instead
of a tyrosine (Tyr) in the conserved class D Y–G–
N motif of the protein at DBL position 144 [28].
A previous report described the presence of
carbapenemase activity in multiresistant A. bau-
mannii isolates from Buenos Aires, Argentina [29].
The present study demonstrates that these iso-
lates contain a novel class D carbapenemase,
which represents a new group of carbapenemases
in A. baumannii.
MATERIALS AND METHODS
Bacterial isolates
Six isolates of A. baumannii were included in this study, all
of which were collected originally between October 1993
and November 1994 from an outbreak involving
carbapenem-resistant A. baumannii in three hospitals in
Buenos Aires, Argentina. The presence of carbapenemase
activity in these isolates, and the results of typing by pulsed-
ﬁeld gel electrophoresis (PFGE), have been reported previ-
ously [30]. Four isolates (779, 780, 781 and 782) originated
from a small teaching hospital. Isolates 786 and 788
originated from a second teaching hospital and a geriatric
hospital, respectively (Table 1).
Antimicrobial susceptibility testing
Antibiotics and inhibitors were obtained as follows: ampicil-
lin, benzylpenicillin, cefotaxime, cefuroxime, cephaloridine,
cloxacillin, oxacillin, EDTA and NaCl from Sigma (Poole,
UK); ciproﬂoxacin from Bayer (Newbury, UK); ceftazidime
from GlaxoWellcome (Uxbridge, UK); imipenem from Merck
Sharp and Dohme (Haddesdon, UK); meropenem from
Zeneca Pharmaceuticals (Macclesﬁeld, UK); rifampicin from
Aventis Pharma (West Malling, UK)1 ; gentamicin from David
Bull Laboratories (Warwick, UK); clavulanic acid and nitr-
ocephin from GlaxoSmithKline (Collegeville, PA, USA); and
sulbactam from Pﬁzer (Sandwich, UK). MICs were deter-
mined according to the guidelines of the Working Party on
Antibiotic Sensitivity Testing [31,32] on IsoSensitest agar
(Oxoid, Basingstoke, UK). Agar plates containing serially
diluted antibiotics were inoculated with a ﬁnal inoculum of
104 CFU ⁄ spot. The recommended NCTC strains were inclu-
ded as controls [31].
Preparation and analysis of b-lactamase extracts
Cell cultures were grown in nutrient broth overnight at 37C
with shaking. Cells were harvested by centrifugation, and cell-
free lysates were prepared by sonication. b-Lactamases were
identiﬁed by isoelectric focusing (IEF) [33], with b-lactamase
activity being detected by an overlay of ﬁlter paper soaked in
nitrocephin (50 mg ⁄L). Known b-lactamases were included as
controls.
Transfer of resistance and curing experiments
Transfer of resistance from representative strain 788 to the
rifampicin-resistant recipient Acinetobacter sp. BD413 was
attempted by the broth [34] and membrane ﬁlter [35]
methods at 25C and 37C, with selection of transconjugants
on nutrient agar plates containing imipenem (4 mg ⁄L) and
rifampicin (50 mg ⁄L). To determine whether imipenem
Table 1. Isolate details and their respective patterns fol-
lowing pulsed-ﬁeld gel electrophoresis (PFGE) [30]
Isolate no. Hospital of origin Isolation date Source
PFGE
pattern
779 CEMICa 2 October 1993 Catheter site A1
780 CEMIC 13 March 1994 Catheter site A1
781 CEMIC 2 May 1994 BAL A2
782 CEMIC 3 November 1994 BAL A3
786 H. de Clinicasb 1994 BAL E
788 Sanatorio Greytonc 21 August 1994 Urine E
aCentro de Educacio´n Me´dica e Investigaciones Clı´nicas teaching hospital.
bHospital de Clı´nicas teaching hospital.
cSanatorio Greyton geriatric hospital.
BAL, bronchial alveolar lavage.
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resistance was plasmid-encoded, curing experiments were
performed by growing cultures overnight at 37C in serial
dilutions of ethidium bromide in nutrient broth. Cured
variants were selected on IsoSensitest agar plates with and
without imipenem (4 mg ⁄L).
b-Lactamase puriﬁcation and determination of molecular
mass
Partial puriﬁcation of OXA-51 from representative strain 788
was performed on a MonoQ anion exchange column by Fast
Protein Liquid Chromatography (FPLC)2 (Amersham Biotech,
Little Chalfont, UK) with a ﬂow rate of 0.5 mL ⁄min. Protein
was eluted in a 1 mM NaCl gradient. Fractions were assayed
with nitrocephin, and the presence of speciﬁc b-lactamases
in positive fractions was determined with IEF. Pooled
fractions were applied to an FPLC Superdex 75 Hiload
20 ⁄ 60 gel ﬁltration column (ﬂow rate of 1.5 mL ⁄min).
Fractions containing b-lactamase were concentrated with a
VectaSpin Micro centrifuge tube ﬁlter (Whatman, Maidstone,
UK). b-Lactamase molecular mass was determined by
sodium dodecyl sulphate–polyacrylamide gel electrophoresis
on a 4–15% linear gradient Tris-HCl gel (Bio-Rad,
Hemel Hempstead, UK). Renaturation of b-lactamase activity
was achieved with Triton X-100 1% v ⁄v at 37C. Activity
was detected by overlaying the gel with nitrocephin
(50 mg ⁄L).
Enzyme kinetics studies
Puriﬁed b-lactamase from strain 788 was assayed, with the
use of a double-beam UV ⁄V Lambda 2 spectrophotometer
(Perkin-Elmer, Beaconsﬁeld, UK), in 50 mM sodium phos-
phate buffer pH 7.0, at 37C for 5 min. Vmax and Km values
were determined by linear regression analysis of Lineweav-
er–Burk plots of initial velocity data obtained at different
substrate concentrations [36]. Inhibition assays (ID50 values)
were performed by incubating b-lactamase with inhibitor
concentrations for 10 min at 37C. Nitrocephin (100 lM) was
added as the reporter substrate, and the initial rates of
hydrolysis were determined.
PCR analysis
DNA was extracted from strains by boiling one to three
colonies in 100 lL of sterile ultrapure water for 10 min and
centrifuging brieﬂy. A 2-lL volume of this crude DNA
extract was used for each PCR. Reactions were carried out in
50-lL volumes containing 20 mM Tris-HCl (pH 8.8), 10 mM
KCl, 10 mM (NH4)2SO4, 2 mM MgSO4, 0.8 mM dNTPs and
1.25 U of Pfu DNA Polymerase (Promega, Southampton, UK).
Ampliﬁcations were performed on a Techne Px2 gradient
thermal cycler (Thermo Hybaid, Middlesex, UK). The primers
employed in this study are listed in Table 2 and were used at
a concentration of 10 pmol ⁄ lL unless otherwise stated.
Ampliﬁcation with subgroup 1- and subgroup 2-speciﬁc
primers
Speciﬁc primers for blaOXA-23 (subgroup 1) were used under
the following conditions: one cycle of 94C for 5 min,
followed by 30 cycles of 94C for 15 s, 35C for 30 s with
a gradient of 15C, and 72C for 1 min, followed by a ﬁnal
extension at 72C for 5 min. Primers for blaOXA-24 (subgroup
2) were used under the following conditions: one cycle of
94C for 4 min, followed by 30 cycles of 94C for 1 min,
50C for 1 min and 72C for 2 min, followed by a ﬁnal
extension at 72C for 10 min. A 498-bp fragment of OXA-51
was ampliﬁed with the use of OXA degenerate primers
(both at 50 pmol ⁄ lL), under the following conditions: one
cycle of 94C for 5 min, followed by 30 cycles of 94C for
1 min, 55C for 1 min and 72C for 1 min, followed by a
ﬁnal extension at 72C for 2 min.
Ampliﬁcation of the OXA-51 gene by a two-step PCR method
A modiﬁcation of a two-step PCR method described by
Sørensen et al. [37] was used to amplify the 5¢-and 3¢-ends of
blaOXA-51. This comprised an initial ampliﬁcation with an
arbitrary partially degenerate primer with a ﬁxed 3¢-end and
an OXA-51-speciﬁc internal primer from the known 498-bp
fragment. A second PCR with 2-lL aliquots of puriﬁed
amplicons was performed with a non-degenerate primer
Table 2. Oligonucleotides used in
this study
Oligonucleotide
primer pairs Application Sequencea Reference
blaOXA-23 PCR of subgroup 1 genes 5¢-CCTCAGGTGTGCTGGTTATTC-3¢ [24]
5¢-CCCAACCAGTCTTTCCAAAA-3¢
blaOXA-24 PCR of subgroup 2 genes 5¢-TTCCCCTAACATGAATTTGT-3¢ [26]
5¢-GTACTAATCAAAGTTGTGAA-3¢
OXA
degenerate
PCR of 498-bp
blaOXA-51 fragment
5¢-CIYTIISIMGIGCIAAYAMIGARTAYG-3¢ This study
5¢-CAICCIGTIARCCAICCIACYTG-3¢
5¢ PCR 1 PCR of 5¢-end of blaOXA-51 5¢-CAGTTCAAGCTTGTCCAGGAATT
CNNNNNNNCGGCA-3¢
[37] and this
study
5¢-TCTGTGGTGGTTGCCTTATG-3¢
5¢ PCR 2 PCR of 5¢-end of blaOXA-51 5¢-CAGTTCAAGCTTGTCCAGGAATTC-3¢
5¢-AGCATTTTGAAGGTCGAA-3¢
[37] and this
study
3¢ PCR 1 PCR of 3¢-end of blaOXA-51 5¢-TAATGCTTTGATCGGCCTTG-3¢
5¢-CTTGTCCAGGAATTCNNNNNNNGGCCT-3¢
[37] and this
study
3¢ PCR 2 PCR of 3¢-end of blaOXA-51 5¢-AAGGCAACCACCACAGAAGT-3¢
5¢-CAGTTCAAGCTTGTCCAGGAATTC-3¢
[37] and this
study
Int PCR of class 1 integron
intI gene
5¢-GTCAAGGTTCTGGACCAGTTGC-3¢ H. K. Young
5¢-ATCATCGTCGTAGAGACGTCGG-3¢
Cass PCR of variable
region of class 1 integron
5¢-TGATCCGCATGCCCGTTCCATACAG-3¢ H. K. Young
5¢-GGCAAGCTTAGTAAAGCCCTCGCTAG-3¢
aI, inosine; Y, any pyrimidine (T or C); S, C or G; M, A or C; R, any purine (A or G); N, AGCT.
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derived from the arbitrary primer, together with a nested
OXA-51-speciﬁc primer. Primers were used at a concentration
of 25 pmol ⁄ lL, with the exception of degenerate arbitrary
primers (75 pmol ⁄ lL). PCRs were run with the following
conditions: one cycle of 94C for 4 min, followed by 40 cycles
of 94C for 1.2 min, 40C with a gradient of 15C for 1.2 min,
and 72C for 3 min, with a ﬁnal extension at 72C for 10 min.
Products (10 lL) were analysed by electrophoresis on agarose
1.5% w ⁄v gels and stained with ethidium bromide. Amplicons
were puriﬁed directly (Qiagen, Crawley, UK), or bands were
excised from a low-melting-temperature agarose 1.5% w ⁄v gel
and puriﬁed (Qiagen). Amplicons from three separate PCRs
were sequenced in both directions on an ABI Prism automated
sequencer (Perkin-Elmer). Protein sequences were aligned
with the use of hierarchical clustering [38].
PCR analysis with class 1 integron primers
Class 1 integron-speciﬁc primers were used under the follow-
ing conditions: 30 cycles of 94C for 1 min, 55C for 1 min and
72C for 3 min, with a ﬁnal extension at 72C for 10 min.
Escherichia coli strain J53 carrying pR388, and strain J53
carrying pR483, were included as positive and negative
controls for PCR analysis.
RESULTS
Bacterial isolates
Two distinct clusters were identiﬁed by PFGE
analysis of bacterial isolates (Table 1). Cluster A
comprised four isolates (779, 780, 781 and 782)
with 90–97% similarity. The remaining two iso-
lates (786 and 788) comprised cluster E; they had
identical PFGE patterns (Table 1).
MICs and IEF analysis of A. baumannii clinical
isolates
With the exception of three isolates (779, 780 and
781) that were sensitive to gentamicin, resistance
was detected in all isolates to all antibiotics tested,
including imipenem (Table 3). MIC values at or
above the recommended breakpoint value were
found for meropenem.
A chromosomal cephalosporinase, which
focused at pI > 8 (data not shown), was detected
by IEF analysis in all isolates. A band that
co-focused with a TEM-1 b-lactamase control
was also present in isolate 786. An unknown
b-lactamase band (pI 7.0) was identiﬁed in all
isolates. This band did not co-focus with the
control b-lactamases and was not present in the
crude extract from an imipenem-sensitive strain
included as a clinical control.
Puriﬁcation and biochemical properties of the
b-lactamase of pI 7.0
A representative isolate (788) was chosen for
further investigation of the pI 7.0 b-lactamase.
The molecular mass of the puriﬁed b-lactamase
was estimated to be 35.5 kDa. Kinetic studies were
performed with puriﬁed b-lactamase. Ampicillin
was the best substrate, indicating that the enzyme
was predominantly a penicillinase (Table 4). None
of the cephalosporins was hydrolysed, with the
exception of cephaloridine (10% relative Vmax).
Slow hydrolysis of imipenem was detected, and
the enzyme had the highest afﬁnity for this sub-
strate, as indicated by a low Km value (Table 4). No
hydrolysis of meropenem was observed, but
hydrolysis of both oxacillin and cloxacillin con-
ﬁrmed that this was an OXA-type enzyme.
For determination of inhibition of b-lactamase
activity, ID50 values of inhibitors were calculated
by preincubating a range of concentrations with
the enzyme and measuring the initial rate of
hydrolysis of a reporter substrate. This demon-
strated inhibition of enzyme activity by sulbactam
Table 3. MICs of clinical isolates
Isolate
no.
MIC values (mg ⁄L)
AMOX CO-AMOX CLD CTX CAZ IMP MER GEN CIP SUL
779 > 128 128 > 128 64 4 8 4 0.5 64 8
780 > 128 128 > 128 64 4 8 4 0.5 32 4
781 > 128 > 128 > 128 64 4 8 4 0.5 32 4
782 > 128 128 > 128 64 4 8 4 8 32 8
786 > 128 > 128 > 128 64 4 8 4 > 64 32 4
788 > 128 128 > 128 64 4 8 8 > 64 32 8
AMOX, amoxycillin; CO-AMOX, co-amoxiclav; CLD, cephaloridine; CTX, cefotax-
ime; CAZ, ceftazidime; IMP, imipenem; MER, meropenem; GEN, gentamicin; CIP,
ciproﬂoxacin; SUL, sulbactam.
Table 4. Kinetic properties and ID50 values of OXA-51
Substrate
Kinetic properties Inhibition studies
Vmax
a (%) Km
b
Relativec
Vmax ⁄Km Inhibitor ID50d
Ampicillin 1498.5 (100) 24 100 Clavulanate 100
Cephaloridine 149.2 (10) 77 3.1 EDTA > 1000
Cefuroxime ND – – Cloxacillin 398
Cefotaxime ND – – Sulbactam 50
Ceftazidime ND – – Sodium chloride 3.2 mM
Imipenem 46.8 (3.1) 11 6.8 Imipenem 2.5
Meropenem ND – – Meropenem 0.004
Oxacillin 484.1 (32.3) 531 1.46
Cloxacillin 31.9 (2.1) 129 0.4
anmoles of substrate hydrolysed ⁄min ⁄mL of enzyme solution.
blM.
cRelative values calculated according to the value obtained for ampicillin, which
was set at 100.
dlM unless otherwise stated. ID50 value deﬁned as the concentration of inhibitor
required to reduce b-lactamase hydrolytic activity by 50%.
ND, not detected (< 0.1).
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and chloride ions (Table 4). Although not inhib-
itors per se, both carbapenems were included in
the inhibitor studies to conﬁrm whether the
b-lactamase was able to bind them via its active
site. Imipenem and meropenem produced 50%
enzyme inhibition at 2.5 lM and 0.004 lM,
respectively (Table 4). Enzyme activity was inhib-
ited weakly by clavulanate. Neither EDTA nor
cloxacillin were efﬁcient enzyme inhibitors. These
results indicated that the pI 7.0 b-lactamase was
an OXA-type class D carbapenemase.
Transfer of imipenem resistance
Broth and membrane ﬁlter matings failed to
demonstrate transfer of resistance in representa-
tive strain 788. In addition, PCRs with class 1
integron-speciﬁc primers were unsuccessful, and
ethidium bromide curing experiments failed to
detect cured variants.
PCR analysis
PCR with primers speciﬁc for the b-lactamase-
encoding genes of OXA subgroups 1 and 2 failed
to amplify the carbapenemase gene in strains 779
(representing PFGE pattern A) and 788 (repre-
senting PFGE pattern E). However, degenerate
primers designed from conserved amino-acid
regions within the genes encoding both subgroup
carbapenemases ampliﬁed an internal 498-bp
gene fragment from both strains. Speciﬁc primers
from within this fragment were paired with
partially degenerate arbitrary primers to amplify
the remaining 5¢ and 3¢ gene regions. Sequencing
of PCR products from both clones identiﬁed a
gene that comprised an 825-bp open reading
frame encoding a 274-amino-acid protein (Fig. 1).
Signiﬁcant differences were identiﬁed when the
amino-acid sequence was compared with those of
subgroups 1 and 2, conﬁrming that the pI 7.0
carbapenemase was novel (Fig. 1). This enzyme
has subsequently been designated OXA-51 and
shares 56% and 61–62% identity with subgroups
1 and 2, respectively. The sequence contained the
conserved serine active site motif S–T–F–K (DBL
numbering 70–73). The K–T–G triad (DBL num-
bering 216–218) was replaced by K–S–G (Fig. 1).
Importantly, OXA-51 differed from both sub-
groups in the sequence of two other conserved
class D motifs. There was a Val ﬁ Ile change in
the S–X–V triad (X denoting any amino acid)
(DBL numbering 118–120), and Tyr of the Y–G–N
motif (DBL numbering 144–146) was retained
(Fig. 1). When OXA-51 was compared with non-
carbapenem-hydrolysing class D enzymes, the
highest similarity was found with OXA-10
(PSE-2) (33%), OXA-5 and OXA-11 (both 32%).
DISCUSSION
This study identiﬁed the emergence of a novel
class D carbapenemase in genetically unrelated
multiresistant clinical isolates of A. baumannii
from Argentina. Class D b-lactamases belong to
group 2d of the Bush functional classiﬁcation
scheme, and are characterised by their ability to
hydrolyse the isoxazolyl penicillins and methicil-
lin [39]. Although they occur predominantly in
Pseudomonas aeruginosa, they have been detected
in other Gram-negative bacteria [22].
The kinetic properties of OXA-51 were not
typical of those of group 2d b-lactamases, in that
only slow hydrolysis of oxacillin and cloxacillin
was demonstrated. Indeed, the Vmax ⁄Km ratio for
oxacillin was over two-fold lower than that
Fig. 1. Comparison of the amino-
acid sequences of OXA-51 and sub-
group 2 class D carbapenemases.
Numbering is in accordance with
the standard DBL numbering sys-
tem [28]. Motifs usually conserved
among class D b-lactamases are
shaded. Dashes indicate identical
amino-acids.
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observed for cephaloridine. With a few excep-
tions, oxacillinases of this group hydrolyse these
b-lactams far more effectively [39]. Among the
carbapenem-hydrolysing oxacillinases character-
ised so far in Acinetobacter, OXA-27 from sub-
group 1 also demonstrated weak activity against
oxacillin [25], while OXA-24 from subgroup 2
failed completely to hydrolyse oxacillin, cloxacil-
lin and methicillin [26]. None of the cephalospo-
rins was hydrolysed by OXA-51, with the
exception of cephaloridine, which was a weaker
substrate than ampicillin. This was a similar
proﬁle to that of the other characterised class D
carbapenemases, although most have demonstra-
ted slow hydrolysis of some cephalosporins [24–
27]. Slow hydrolysis of imipenem by OXA-51 was
detected, but not of meropenem, and this was also
demonstrated with OXA-23 and OXA-40 [27,40].
In contrast, the other class D carbapenemases
were reported to hydrolyse both substrates, albeit
slowly [25,26]. Importantly, however, OXA-51
had the highest afﬁnity for imipenem, as demon-
strated by the lowest Km value.
Inhibition of OXA-51 activity was detected with
NaCl (a class D inhibitor), and this was also
reported for OXA-24 [26]. Inhibition was also
detected with the class A inhibitor clavulanic
acid, which also inhibits most class D enzymes
[39]. With the exception of OXA-23 [24] and OXA-
40 [27], the ID50 value detected for OXA-51 with
this inhibitor was higher than the values observed
for the other class D carbapenemases in sub-
groups 1 and 2. Despite the lack of meropenem
hydrolysis by OXA-51, low ID50 values were
determined for imipenem and meropenem, indi-
cating high enzyme afﬁnity for both carbapenems.
Failure of the metal ion chelator EDTA to inhibit
the activity of OXA-51 conﬁrmed that it was not a
metallo-b-lactamase, all of which are character-
ised by the requirement for a zinc ion at their
active site [39].
Signiﬁcant amino-acid differences were identi-
ﬁed when the sequence of OXA-51 was compared
to those of subgroups 1 and 2. In particular,
changes were observed within conserved struc-
tural motifs that are important for the functioning
of the enzyme active site [39,41]. OXA-51 had a
Thr ﬁ Ser change in the K–T–G motif (DBL
numbering 216–218), as seen in the subgroup 2
carbapenemases [25–27], but not in subgroup 1
enzymes [24,25]. A unique Val ﬁ Ile change in
the S–X–V motif, that is not present in the other
class D carbapenemases sequenced, was identi-
ﬁed. Importantly, OXA-51 also retains the Y–G–N
motif (DBL 144–146), in contrast to the carba-
penemases of subgroups 1 and 2, in which Tyr of
this motif is replaced by Phe [24–27]. Conse-
quently, OXA-51 is the ﬁrst class D carbapene-
mase to be found in Acinetobacter that lacks this
substitution. This ﬁnding contradicts the general
opinion that substitution of Tyr with Phe in these
carbapenemases confers hydrolytic activity
against the carbapenems [24,26]. Site-directed
mutagenesis experiments with OXA-40 have indi-
cated that this residue change is not solely
responsible for carbapenem-hydrolysing activity
as originally thought, but rather, that it confers
overall weak hydrolytic activity [27]. In terms of
structure–function relationships, further research
is required to determine the signiﬁcance of these
changes.
OXA-51 is the ﬁrst class D carbapenemase to be
sequenced in A. baumannii clinical isolates from
Argentina. The biochemical properties of another
carbapenemase from a single isolate in Buenos
Aires have been reported [42]. Some differences
were observed in their kinetics, in that oxacillin
was a better substrate for this enzyme than for
OXA-51, but it was less active against imipenem
in terms of Vmax ⁄Km. The gene encoding this
b-lactamase has never been sequenced, and it
remains to be determined whether it is related to
OXA-51.
The presence of OXA-51 in different clones of
A. baumannii obtained from three hospitals within
Buenos Aires indicated that horizontal transfer
of the encoding gene had occurred. However,
attempts to transfer imipenem resistance by
conjugation failed, although conjugation in Acine-
tobacter spp. is notoriously difﬁcult to achieve
[43]. In addition, PCR with class 1 integron prim-
ers proved unsuccessful, and imipenem-sensitive
variants were not detected in curing experiments.
With the exception of OXA-23, which has been
shown to be plasmid-encoded [44], the class D
carbapenemases described so far in A. baumannii
are reported to be chromosomally located [25–27].
In addition, none has been associated with mobile
elements such as integrons, which would facili-
tate their transfer. This is unusual, since most of
the conventional class D b-lactamase genes in
Enterobacteriaceae and Pseudomonas are on large
transferable plasmids, often within the gene
cassettes of integrons [22]. However, OXA-23
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has also been found in several clonally related
strains of Proteus mirabilis, although the presence
of this carbapenemase was not sufﬁcient in
itself to cause an increase in the MIC of imipe-
nem above the breakpoint for these strains [45].
OXA-40 has been discovered in two clones of
A. baumannii [11], even though its encoding gene
has been reported to be chromosomally located,
and analysis of the ﬂanking sequences has provi-
ded no evidence to suggest that it is associated
with an integron structure [27].
The origin of these unusual carbapenemases
remains unclear. They may have always been
present in a number of Acinetobacter strains,
perhaps as a resistance mechanism against anti-
biotic-producing soil microorganisms. Imipenem
is a derivative of thienamycin, a natural product
of Streptomyces cattleya [46]. OXA-23 was discov-
ered in an imipenem-resistant clinical isolate from
a patient in 1985, before imipenem was in use
[23]. In addition, a region upstream from the gene
encoding this carbapenemase was found to have
90% homology with a sequence previously iden-
tiﬁed in Acinetobacter strains isolated from sludge
[24]. Alternatively, related genes may have spread
into Acinetobacter spp. from unknown source
organisms on plasmids that have subsequently
become integrated into the chromosome. A plas-
mid-encoded class D carbapenemase (OXA-48)
that has recently been discovered in a carbape-
nem-resistant Klebsiella pneumoniae strain in Tur-
key [47] shares 92% amino-acid identity with a
novel class D carbapenemase (OXA-54) found in
an environmental reference strain of Shewanella
oneidensis [48]. In addition, a clinical isolate of
Shewanella algae has been found to harbour a
chromosome-encoded class D b-lactamase which
hydrolyses carbapenems, albeit slowly [49]. These
ﬁndings shed some light on the potential reser-
voirs of class D carbapenemases. Comparison of
OXA-48 and OXA-54 with OXA-51 identiﬁed
amino-acid similarities of only 32% and 33%,
respectively. Importantly, however, as with OXA-
51, the Y–G–N motif is conserved in OXA-48,
OXA-54 and OXA-55 [47–49].
Whatever their origin, the incidence of class D
carbapenemases in Acinetobacter is increasing
and is now of major clinical concern. Within
the last year, OXA-23 has been reported in
genetically related carbapenem-resistant strains
from Brazil [50], in an A. junii strain from China
(GenBank ⁄EMBL accession number AY554200)
and in two A. baumannii clones from England
[51], some 11 years after it was ﬁrst reported.
Importantly, these multiresistant strains are
contributing to the deaths of patients, as neither
complex combination therapy nor treatment
with polymyxin B (which has been shown to
have in-vitro activity against some multiresistant
strains) is guaranteed to succeed [10,50,52].
From the results of the present study, we
conclude that OXA-51 is the ﬁrst of a new
subgroup of class D carbapenemases to emerge
in A. baumannii. It can be anticipated that the
incidence of carbapenem-resistant strains will
continue to increase, which will have a severe
impact on future therapeutic choices for infec-
tions caused by this pathogen.
Nucleotide sequence accession number
The sequence data reported in this paper will
appear in the GenBank ⁄EMBL nucleotide data-
base under accession no. AJ309734.
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